Latest Financial Performance News

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.

EQ Resources delivered a breakout quarter with A$79 million revenue and A$22.5 million operating cash flow, driven by a 176% production surge at Mt Carbine and soaring tungsten prices. The company greenlit a major expansion to double crushing capacity, targeting commissioning in Q3 FY2027.

Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.

Aeeris Ltd has boosted its Annual Recurring Revenue by 9.1% year-on-year to $3.84 million, driven by an 18.6% rise in fixed subscription revenue and a strategic shift towards enterprise clients.

Talius Group maintained steady revenue in Q2 2026, boosted by $2 million in new aged care contracts and a 10% increase in active subscriptions.

Wide Open Agriculture (ASX: WOA) is executing a major strategic pivot by closing its German production site and transitioning to a capital-light contract manufacturing model to improve economics and scale lupin protein production.

Wisr has reported its first full-year Cash NPAT profit of $1.0 million in FY26, driven by record loan originations and improved credit metrics, while lifting FY27 guidance to at least $5.0 million.

Genesis Minerals delivered record FY26 gold production within guidance, boosted cash flow, accelerated key projects, and agreed to merge with Vault to create a top 20 global gold producer.

Desane Group Holdings progresses key developments in Penrith and Leichhardt, with construction milestones and tenant arrangements set to boost recurring income.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.